



PET/GB03/4725



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 19 FEB 2004

WIPO PCT


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



P. Mahoney


Signed

Dated 6 November 2003

Patents Act 1977
(Rule 16)

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



86W02 E760871-2 002882
P01/7700 0.00-0225676.6

The Patent Office

Concept House
Cardiff Road
Newport
South Wales NP10 8QQ

1. Your reference SCB/NLW/61737/000
2. Patent application number 0225676.6
(The Patent Office will fill in this part) = 4 NOV 2002
3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

Patents ADP number (*if you know it*)

If the applicant is a corporate body, give the country/state of its incorporation

G W Pharma Limited
Porton Down Science Park
Salisbury
Wiltshire
SP4 0JQ
United Kingdom

8331340001
GB
4. Title of the invention NEW USE FOR PHARMACEUTICAL COMPOSITION
5. Name of your agent (*if you have one*) BOULT WADE TENNANT

"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*) VERULAM GARDENS
70 GRAY'S INN ROAD
LONDON WC1X 8BT

Patents ADP number (*if you know it*) 42001
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

	Country	Priority application number (if you know it)	Date of filing (day/month/year)
--	---------	---	------------------------------------
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

	Number of earlier application	Date of filing (day / month / year)
--	-------------------------------	--
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? YES
(Answer 'Yes' if:
a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form -

Description 7

Claim(s) 2 DM 1

Abstract -

Drawing(s) 3 + 3

10. If you are also filing any of the following, state how many against each item.

Priority documents -

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77) 1 ✓

Request for substantive examination (Patents Form 10/77)

Any other documents (Please specify)

11 I/We request the grant of a patent on the basis of this application.

Signature

Date

Rout Wade Tennant

4 November 2002

12. Name and daytime telephone number of person to contact in the United Kingdom Martyn J. Draper
020 7430 7500

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

DUPLICATE

GW REF P0020

NEW USE FOR PHARMACEUTICAL COMPOSITION

The brachial plexus is formed from a group of combining spinal nerves that eventually divide to form the entire motor and sensory supply to the upper limb. Trauma to these nerves is associated with paralysis, loss of sensation and frequently chronic pain. Initial treatment is to repair the nerve damage through surgery. Although this surgery is often successful in restoring motor function, patients are often left with long term pain. The few studies which have reviewed pain following brachial plexus injury have shown that this pain is particularly difficult to treat.¹ Drugs are available to treat the pain but they have limited efficacy and are often associated with side effects. Improved treatments are urgently needed for this patient group.

Cannabis plants (*Cannabis sativa*) contain over 60 different cannabinoids². In the UK until 1971, British Doctors could prescribe oral tinctures of cannabis.³ Subsequently, cannabis and cannabinoids were placed in Schedule 1 of the Misuse of Drugs Act 1971 and for the past four decades, cannabis has been associated with illicit recreational use, largely by smoking dried plant material or resin from the flower heads to obtain a rapid absorption from the lung, giving a euphoric state or 'high'. The principal psychoactive component in cannabis preparations is considered to be the cannabinoid Δ^9 tetrahydrocannabinol (THC).

Cannabinoids affect almost every body system and like any other drug may have side effects.⁴ These are not usually severe and compare favourably with many other drugs with similar therapeutic targets for example; tricyclic antidepressants, phenothiazines, opioid and non-opioid analgesics and anticonvulsants. It has been estimated, based on extrapolation from mouse to man, that the lethal dose to effective dose (LD/ED) ratio is about 40,000 to 1.⁶ There have been no recorded deaths directly attributable to cannabis alone whereas in the UK approximately 600 people die each year following gastrointestinal haemorrhage, largely associated with NSAID use.⁷

Known pharmacological effects of cannabinoids⁴ include psychological effects, effects on perception, cognition, psychomotor performance and motor function, and analgesic, anti-emetic and sedative effects. Cannabinoids are known to cause a decrease in intra-ocular pressure and an increase in appetite. There are also cardiovascular effects; tachycardia and increased cerebral blood flow (with acute use), bradycardia and decreased cerebral blood flow (with chronic use), vasodilation and increased cardiac output. Effects on the respiratory system include bronchodilatation, airways obstruction (from smoking), and effects on ventilation. Aggravation of psychosis may occur in patients with schizophrenia.

Whether the recreational use of cannabis encourages escalation of dosage and progression to other dependency-producing drugs remains debatable. Many other therapeutic drugs have an abuse potential that might be considered to be more harmful and less reversible such as; benzodiazepines and opioids. However, experience with patients receiving opioids for pain relief shows that therapeutic use rarely leads to misuse,^{8,9} and the same is likely to apply to cannabinoids. Withdrawal symptoms from cannabinoid use are said to be short-lived (a few days) and mild in normal experimental subjects.³ Experience with the clinical use of Nabilone indicates that this is probably a minor and occasional problem. Psychological dependency definitely occurs in a small minority of recreational users. Some workers take the view that there is also a modest physical withdrawal syndrome when heavy users abruptly abstain,⁴ though this seems to be limited to a few nights of sleep disturbance and somatic anxiety symptoms.

A body of anecdotal evidence has emerged that suggests that patients with a range of conditions and diseases can obtain significant symptom relief from illicit or 'street' cannabis. The evidence base includes reports from patients with rheumatoid arthritis, neuropathic pain, cancer pain and multiple sclerosis (MS).⁶ Cannabis use has tended to happen amongst patients with severe or intolerable symptoms that conventional therapies had failed to relieve and who had tried cannabis as a last resort. Subsequently, interest has grown and research has been conducted into the therapeutic uses of cannabinoids.² This research has not been part of a coordinated programme and has involved small trials, often in single indications and has focussed mainly on purified oral formulations of the main psychoactive component, THC. One placebo-controlled study of oral THC in nine patients showed a statistically significant reduction in spasticity compared with placebo.¹² A second placebo controlled study of oral THC in 13 patients reported significant subjective improvements in spasticity.¹³ In many other cases however, the results have been inconclusive, but benefits have been evident even in small trials. These contradictory results are probably because routes of administration involving the gastro-intestinal tract (oral, rectal) are slow and produce variable effects, due to the poor and varied absorption from the gut. In these settings it has been difficult to titrate cannabinoids accurately to a therapeutic effect.

Currently the synthetic cannabinoid Nabilone[®] is the only cannabinoid preparation with a licence for medicinal use in the UK. Nabilone[®] capsules are indicated for intractable nausea and vomiting associated with cytotoxic chemotherapy. There has been insufficient evidence to secure regulatory approval in any other indications. Purification of a single cannabinoid may be a contributory factor in limiting efficacy in therapeutic areas where strong anecdotal evidence has suggested a therapeutic benefit from smoked cannabis. A mixture of many cannabinoids is delivered when cannabis is smoked,² but smoking clearly is an inappropriate

delivery system for a medicinal product. The smoke is inconsistent in composition and contains potential carcinogens from incomplete combustion, similar to tobacco smoke.⁴

The findings of the House of Lords Select Committee on Science and Technology recommended that clinical trials of cannabis for the treatment of MS and chronic pain be mounted as a matter of urgency and that research should be promoted into alternative modes of administration which would retain the benefits of the rapid absorption offered by smoking without the associated adverse effects (Section 28, References, 1). The Institute of Medicine report on medicinal cannabis also recommended that therapeutic trials be undertaken on non smoked forms of cannabis-based medicines.¹¹

The applicant has developed cannabis based medicinal extracts (CBME), from whole cannabis plants as disclosed in WO 02/064109. The extracts are derived from strains of plants developed to produce high and reproducible yields of specified cannabinoids. The extracts from these plants contain a defined amount of the major cannabinoid, plus trace amounts of minor cannabinoids. The major cannabinoids constitute not less than 90% of the total cannabinoid content of the extracts. It is thought that the minor cannabinoids may add to the overall therapeutic profile of the CBMEs and may play a role in stabilising the major components. Currently, two CBME preparations have reached phase 3 clinical studies, "THC" in which Δ^9 tetrahydrocannabinol is the major cannabinoid, and "THC:CBD 1:1", containing substantially equal proportions of THC and cannabidiol (CBD) as the major cannabinoids.

Sublingual and inhaled CBME preparations have been developed, to achieve rapid absorption of the type seen from smoking cannabis, and minimise absorption by the oral route, which is subject to first pass metabolism. Evidence collected from pooled phase 2 "n of 1" studies (single case within patient crossover studies)^{5,10} has indicated that these routes of administration are not associated with the titration problems of the oral route. CBME dosing is similar to patient controlled analgesia (PCA), most commonly used to deliver opioids for control of post-operative pain. Small increments are delivered each time patients require them, up to a maximum daily limit. The phase 2 "n of 1" data have helped to define the effective dose delivered per actuation, and the recommended maximum doses. The data also indicate that the therapeutic benefits of CBMEs are delivered at doses below those which cause a sensation of a 'high', and that onset of the 'high' may be an indicator of overtitation.

A large proportion of the MS patients who reported peripheral pain as part of their symptomatology in the "n of 1" studies showed marked improvement in pain scores with CBME therapy, usually with few persisting side-effects once the optimum dose had been

reached.¹⁰ Peripheral MS pain may have a neuropathic element but is often multifactorial. Pain of purely neuropathic origin in MS is difficult to diagnose clinically. Studies were set up to investigate and study the efficacy of CBME in relieving neuropathic pain and chronic pain following brachial plexus injury. In this condition, chronic pain is attributed to nerve injury, that is, it is neuropathic in origin.

Of primary interest in this study is the efficacy of CBME in relieving neuropathic pain, in comparison to placebo. Brachial plexus injuries may follow stretching caused by shoulder dislocation (dystocia), breach extraction or hyper abduction of the neck in abnormal presentations during labour. The injuries can be due to simple stretching, haemorrhage within a nerve, tearing of the nerve or root or avulsion of the roots with associated cervical cord injury. The injuries may also be due to trauma of the clavicle or humerus or subluxation of the shoulder or cervical spine. There are a number of other conditions such as ERB's Palsy (upper brachial plexus injury) (lower plexus injury). All of these conditions are examples of neuropathic pain and are responsible for considerable morbidity. The prognosis for recovery in any of these conditions is poor and the pain associated with them is excruciating. To date there is very little that can be done to relieve pain in patients with these conditions.

Surprisingly, it has been found that extracts of cannabis containing as principal cannabinoids Δ^9 -tetrahydrocannabinol (THC) and cannabidiol (CBD) in differing proportions are not only effective, but are so at low doses.

In this regard the applicant has previously determined that in order to treat pain in Multiple Sclerosis patients it has typically been necessary to provide a daily dose in the range of 30-50mg.

Thus, the term low dose as used herein refers to a mean daily dose of less than 40mg.

According to a first aspect of the present invention there is provided the use of one or more cannabinoids in the manufacture of a medicament for use in the treatment of neuropathic or chronic pain.

In one embodiment the medicament is provided in a form capable of delivering a mean daily dose of less than 37.5 mg.

Where the medicament is packaged for delivery as e.g. a sub lingual or buccal spray a typical mean daily dose will be less than 25 mg, and typically in the range 5-25mg.

Preferred cannabinoids are THC and / or CBD, more preferably in the form of a CBME.

According to a second aspect of the present invention there is provided the use of one or more cannabinoids in the manufacture of a medicament for use in the treatment of sleep disturbance.

The invention is further described, by way of example only, with reference to the following Examples and Figs in which:

Fig 1 shows diary card data for treatments with a high THC or THC/CBD CBME. Pain Score is compared to baseline and placebo;

Fig 2 shows diary card data showing sleep disturbance scores (change from baseline) for treatments with a high THC or THC/CBD CBME;

Fig 3 shows diary card data showing sleep disturbance scores for treatments with a high THC or THC/CBD CBME. Sleep disturbance is compared to baseline and placebo.

Fig 4 shows pain review scores treatments with a high THC or THC/CBD CBME.

In clinical trials of cannabis extracts, fractional doses of 2.5 mg were given to patients with conditions such as the pain of multiple sclerosis to achieve a total daily dose of approximately 40-50 mg of THC or this dose of THC combined with an equal quantity of CBD. In refractory condition such as brachial plexus avulsion (BPA) it might be expected that higher doses would be required which would take the total daily dose into the range where cognitive impairment was produced in patients. Surprisingly it was found that patients with BPA who were treated with the same preparations obtained significant relief at doses of approximately one half of this level. It was also noted that objective measurements of pain (box scale 11 – a validated pain score) showed that THC and CBD produced statistically significant reductions in BS11 pain score and both were highly significantly different from placebo and base line scores. Sleep disturbance was also reduced by THC, and THC in combination with CBD, and there was also an improvement in sleep quality at week 2. Both THC and CBD produced statistically highly significant improvement.

Example 1

A clinical trial was carried out in 48 patients with chronic pain due to brachial plexus injury. This was a double blind, randomised, three-way crossover study comparing two different sublingual cannabis-based medicine extracts (CBMEs) with placebo. The active treatments were given in the form of a sublingual spray. Each spray contained 2.5 mg of THC or 2.5 mg of THC plus 2.5 mg of CBD in the form of an alcoholic solution of a cannabis extract. The

patients titrated the dose up to the level at which pain relief was obtained; assessments were made by the patient diary scores and by the clinicians and nursing staff.

Fig 1 shows the diary card scores based on the box score 11 (BS11) in comparisons with placebo. The mean number of sprays for the patients receiving THC was 7.26 and for the 1:1 ratio THC : CBD was 6.93, compared with 7.15 for placebo. These doses correspond to total daily doses of approximately 18 mg for THC and 17 mg when THC was given in conjunction with CBD.

A further surprising finding was that the number of sleep disturbances in these patients (who have their sleep duration and quality frequently disturbed) obtained improvement in this parameter. Figs 2 and 3 show that sleep disturbance scores at week 2 were highly significantly statistically improved both with THC and the THC:CBD combination compared with placebo.

Fig 4 shows pain review scores showing the effect of THC and THC:CBD in 1:1 ratio at week 2. The differences from placebo was highly significantly statistically, not only by diary card but by mean pain review score (clinician assessment).

Significantly the relief of pain in these patients from the cannabis extract was achieved at doses which did not cause significant cognitive impairment.

Comparative Example

In previous studies, which examined the effect of cannabis-based medicine on pain relief in multiple sclerosis, pain relief was typically achieved in the range 25-50 mg/day approximately.

It is therefore surprising that in patients with neuropathic pain, particularly brachial plexus pain, which is notoriously difficult to treat, relief was obtained at lower doses.

References

1. Berman J, Birch R, Anand P. Pain following human brachial plexus injury with spinal cord root avulsion and the effect of surgery. *Pain* 1997;75:199-207.
2. Mechoulam R. Cannabinoid chemistry. In: Marijuana – chemistry, pharmacology, metabolism and clinical effects. Mechoulam R ed. Academic Press, London. 1973:1-99.
3. Therapeutic uses of cannabis. British Medical Association. 1997. 1-6. Harwood Academic Publishers. Morgan DR ed.
4. Ashton CH. Adverse effects of cannabis and cannabinoids. *Br J Anaesth* 1999;83:637-49.
5. Investigator Brochure - Cannabis based medicine extract sublingual formulations. GW Pharmaceuticals plc, February 2001, Edition 5.
6. Grinspoon L, Bakalar JB. Marijuana, the forbidden medicine. 1993. Yale University Press, 138.
7. *Prescribers Journal* 1998;38.4:213.
8. Porter J, Jick H. Addiction rare in patients treated with narcotics. *N Engl J Med* 1980;802:123.
9. Portenoy RK. Chronic opioid therapy in non-malignant pain. *J Pain Symptom Manage* 1990;5 (Suppl 1):46-62.
10. Unpublished data. GW Pharmaceuticals plc.
11. House of Lords Select Committee on Science and Technology: Cannabis: The scientific and medical evidence. 1998;9th Report.
12. Petro DJ, Ellenberger C. Treatment of human spasticity with Δ^9 tetrahydrocannabinol. *J Clin Pharmacol* 1981;21:413S-416S.
13. Ungerleider JT, Andrysiak T, Fairbanks L et al. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. *Adv Alc Subs Abuse* 1988;7:39-50.

CLAIMS

1. The use of one or more cannabinoids in the manufacture of a medicament for use in the treatment of neuropathic or chronic pain.
2. The use of one or more cannabinoids as claimed in claim 1 wherein the one or more cannabinoids comprise Δ^9 -tetrahydrocannabinol (THC).
3. The use of one or more cannabinoids as claimed in claim 1 wherein the one or more cannabinoids comprise cannabidiol (CBD).
4. The use of one or more cannabinoids as claimed in any of the preceding claims wherein the one or more cannabinoids comprise both THC and CBD.
5. The use of one or more cannabinoids as claimed in claim 4 wherein the THC and CBD are provided in a ratio of between 2:1 and 1:2.
6. The use of one or more cannabinoids as claimed in claim 5 wherein the THC and CBD are provided in a ratio of substantially 1:1.
7. The use of one or more cannabinoids as claimed in any of the preceding claims wherein the medicament is provided in a form capable of delivering a mean daily dose of less than 37.5 mg THC.
8. The use of one or more cannabinoids as claimed in any of the preceding claims wherein the medicament is packaged for delivery as a sub lingual or buccal spray to provide a daily dose of less than 25 mg THC.
9. The use of one or more cannabinoids as claimed in any of the preceding claims wherein the cannabinoids are present as a CBME.
10. The use of one or more cannabinoids as claimed in any of the preceding claims wherein the neuropathic pain is brachial plexus avulsion.
11. The use of one or more cannabinoids in the manufacture of a medicament for use in the treatment of sleep disturbance.
12. The use of one or more cannabinoids as claimed in claim 11 wherein the one or more cannabinoids comprise Δ^9 -tetrahydrocannabinol (THC).
13. The use of one or more cannabinoids as claimed in claim 11 wherein the one or more cannabinoids comprise cannabidiol (CBD).

14. The use of one or more cannabinoids as claimed in any of claims 11-13 wherein the one or more cannabinoids comprise both THC and CBD.

15. The use of one or more cannabinoids as claimed in claim 14 wherein the THC and CBD are provided in a ratio of between 2:1 and 1:2.

16. The use of one or more cannabinoids as claimed in claim 15 wherein the THC and CBD are provided in a ratio of substantially 1:1.

17. The use of one or more cannabinoids as claimed in any of claims 11-16 wherein the medicament is provided in a form capable of delivering a mean daily dose of less than 37.5 mg THC.


18. The use of one or more cannabinoids as claimed in any of claims 11-17 wherein the medicament is packaged for delivery as a sub lingual or buccal spray to provide a daily dose of less than 25 mg THC.

19. The use of one or more cannabinoids as claimed in any of claims 11-18 wherein the cannabinoids are present as a CBME.

20. The use of one or more cannabinoids as claimed in any of claims 11-19 wherein the sleep disturbance is caused by brachial plexus avulsion.

FIG 1.


Study BP0101 **Diary Card Data** **Mean BS11 Pain Scores at Week 2**



188

FIG 2.


Study BP0101- Diary Card Data **Sleep Disturbance Scores at Week 2**



190

FIG 3.


Study BP0101- Diary Card Data Sleep Quality Scores at Week 2



192

FIG.4

Study BP0101- CRF Data Pain Review Scores at Week 2



194

PCT Application
GB0304725

